Innovative therapeutics

Investors

BioMarin Announces 3 Platform and 15 Poster Presentations at 13th International Congress of Inborn Errors of Metabolism 2017
Sep 5, 2017

SAN RAFAEL, Calif., Sept. 5, 2017 /PRNewswire/ -- BioMarin (Nasdaq:BMRN) announced that the company will present data in three platform presentations and fifteen poster presentations at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) being held September 5-8, 2017 in Rio de Janeiro, Brazil. Presentations span a range of areas in rare genetic diseases, including neuronal ceroid lipofuscinosis type 2 (CLN2) disease, phenylketonuria (PKU) and mucopolysacchardosis (MPS).

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

Platform presentations include preliminary safety and pharmacodynamic response data from a Phase 1/2 study of ICV BMN 250, a novel enzyme replacement therapy for the treatment of Sanfilippo B (MPS IIIB), a long-term safety and efficacy analysis of cerliponase alfa to treat children with CLN2 disease, as well as updated five-year safety and efficacy data evaluating pegvaliase to treat adults with PKU.

Listing of Posters and Presentations Related to BioMarin Products and Programs at the 13th International Congress of Inborn Errors of Metabolism (All times are local)

Platform Presentations

Title

Authors

Preliminary safety and pharmacodynamics response data from a phase 1/2 study of ICV BMN 250, a novel enzyme replacement therapy for the treatment of Sanfilippo syndrome type B (MPS IIIB)

 

Parallel Session 1: Wednesday, September 6 from 12:00-12:15

Steve Maricich, MD, PhD, BioMarin Pharmaceutical Inc. Novato, CA, USA

Long-term safety and efficacy of intracerebroventricular enzyme replacement therapy with cerliponase alfa in children with CLN2 disease: interim results from an ongoing multicenter extension study

 

Parallel Session 1: Wednesday, September 6 from 12:00-12:15

Marina Trivisano, MD, Bambino Gesú Children's Hospital, IRCCS, Rome, Italy

Phase 2 long-term pegvaliase treatment for adults with phenylketonuria: updated year 5 safety and efficacy data from the PAL-003 extension

 

Parallel Session 7: Wednesday, September 6 from 14:45-15:00

Jerry Vockley, MD, PhD, Children's Hospital of Pittsburgh and University of Pittsburgh, Pittsburgh, PA, USA

Poster Presentations

MPS


Title

Authors

Design and rationale of ongoing observational and treatment studies for BMN 250, a novel enzyme replacement therapy for Sanfilippo syndrome type B (MPS IIIB)

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 597

Shaywitz A, Maricich S, Yu H, Kent S

Presenting signs and symptoms of MPS: results of an international physician survey

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 649

Clarke L, Ellaway C, Foster H, Giugliani R, Goizet C, Goring S, Hawley S, Jurecki E, Khan Z, Lampe C, Martin K, McMullen S, Mitchell J, Mubarack F, Muenzer J, Sivri S, Stewart F, Tylki-Szymanska A, White K, Wijburg F

Presenting signs and symptoms of MPS: results of systematic literature analysis

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 662

Mubarack F, Clarke L, Ellaway C, Foster H, Giugliani R, Goizet C, Goring S, Hawley S, Jurecki E, Khan Z, Lampe C, Martin K, McMullen S, Mitchell J, Muenzer J, Sivri S, Stewart FJ, Tylki-Szymanska A, White K, Wijburg F

Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: a review of published classified variants in the ARSB gene

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 674

Tomanin R, Karageorgos L, AlSayed M, Bailey M, Izzo E, Miller N, Sakuraba H, Zanetti A, Hopwood JJ

Impact of elosulfase alfa treatment on patient-reported outcomes in Morquio A syndrome: results from the first year of an English managed access agreement

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 807

Lavery C, Jones SA, Hughes D, Murphy E, Jovanovic A, Hendriksz C, Cleary M, Hiwot T, Vijay S

 

CLN2


Title

Authors

Long-term safety and efficacy of intracerebroventricular enzyme replacement therapy with cerliponase alfa in children with CLN2 disease: interim results from an ongoing multicenter extension study

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 787

Trivisano M, Schulz A, Specchio N, Gissen P, de los Reyes E, Cahan H, Slasor P, Ajayi T, Jacoby D

 

PKU


Title

Authors

Phase 3 PRISM-2 long-term extension study evaluating efficacy and safety of pegvaliase for treatment of adults with phenylketonuria

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 285

Vockley J, Levy H, Amato S, Zori R, Thomas J, Burton B, Harding C, Longo N, Posner J, Bilder D, Olbertz J, Gu Z, Lau K, Lin M, Larimore K, Dimmock D

Phase 2 long-term pegvaliase treatment for adults with phenylketonuria: updated year 5 safety and efficacy data from the PAL-003 extension

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 288

Zori R, Levy H, Longo N, Lau K, Rosen O, Li M, Larimore K, Decker C, Weng H, Vockley J

Seventh interim analysis of the Kuvan® Adult Maternal Paediatric European Registry  (KAMPER): interim results in BH4 deficiency patients

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 295

Van Spronsen FJ, Burlina A, Alm J, Belanger-Quintana A, Feillet F, Lagler FB, Muntau AC, Trefz FK, Jurecki ER, Kittus R, Alvarez I

Seventh interim analysis of the Kuvan® Adult Maternal Paediatric European Registry  (KAMPER): interim results in phenylketonuria patients

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation:296

Van Spronsen FJ, Muntau AC, Lagler FB, Feillet F, Alm J, Burlina A, Belanger-Quintana A, Alvarez  I, Lilienstein J, Jurecki E, Trefz FK

Interim analysis of the phenylketonuria (PKU) patients enrolled in the PKUDOS registry

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation:297

Lilienstein J, Burton B, Grant M, Ficicioglu C, Kopesky J, Nguyen-Driver MD, Moore C, Jurecki E, Longo N

An interim analysis of the Kuvan®Adult Maternal Paediatric European Registry  (KAMPER) and phenylketonuria developmental outcomes and safety (PKUDOS) registries: pregnancies

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 298

Feillet F, Ficicioglu C, Lagler FB, Longo N, Alm J, Muntau AC, Burlina A, Belnager-Quintana A, Trefz FK, Kittus R, Jurecki E, Alvarez I, Lilienstein J, Burton B

Estimation of resource use and quality of life in phenylketonuria (PKU) patients in Ireland

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 262

Pastores G, Bracken J, Hughes J, Rogers Y, Stenson C, Clark A, Lloyd A, Alvarez I, Jain M, Kha A, Monavari A

Short-term biological variance of PHE in patients with phenylketonuria

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 250

Potter M, Pendar A, Langley E, Geraghty M

Amino acid level correlations between tandem mass spectrometry and ultra-performance liquid chromatography and the clinical relevance for phenylketonuria management

 

Presentation: Wednesday, September 6 from 17:30-20:00

 

Poster/Presentation: 251

Potter M, Pendar A, Langley E, Geraghty M

Links to Full Prescribing Information on BioMarin Products

www.Brineura.com 

www.kuvan.com

www.Naglazyme.com

www.VIMIZIM.com 

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.

Contact:

Investors:

Media:

Traci McCarty 

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

 

SOURCE BioMarin Pharmaceutical Inc.


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information